IOVANCE BIOTHERAPEUTICS, INC. Notes Payable, Noncurrent
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Notes Payable, Noncurrent of $1.00 million as of 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermNotesPayable · last filed 2026-02-24
- 2024-12-31: Notes Payable, Noncurrent $1.00M.
- 2024-09-30: Notes Payable, Noncurrent $1.00M.
- 2024-06-30: Notes Payable, Noncurrent $1.00M.
- 2024-03-31: Notes Payable, Noncurrent $1.00M.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2024-12-31 | $1.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.00M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.00M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.00M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $1.00M 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.00M 10-K · filed 2023-02-28 |
| 2021-09-30 | $1.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |